Interleukin-2 for active dermatomyositis
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 75 (including 18 and 75).
- Have a confirmed diagnosis of dermatomyositis, using accepted classification methods.
- Have active disease right now, based on muscle strength tests and/or skin disease activity scores and lab blood tests.
- Be on a stable, lower dose of steroid (prednisone equivalent under 0.5 mg/kg/day) for at least 4 weeks, or not start new immune medicines in the last 12 weeks.
- Sign the informed consent form and agree to follow study visits and procedures.
- If you can become pregnant, use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This trial tests an investigational drug called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rashes. The goal is to see if the drug can help control the disease.
This trial tests a treatment called 3T therapy for people with MDA5-positive dermatomyositis, a rare autoimmune disease that affects the skin, muscles, and often the lungs. The goal is to see if 3T therapy can help control the disease and improve lung function.
This trial tests an experimental therapy (PN-101) made from donated mitochondria, which are tiny energy-producing parts of cells. It is for adults with refractory (hard-to-treat) polymyositis or dermatomyositis. The goal is to see if PN-101 can improve muscle strength and reduce disease activity.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.